128 related articles for article (PubMed ID: 10490737)
41. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
[TBL] [Abstract][Full Text] [Related]
42. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
[TBL] [Abstract][Full Text] [Related]
43. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
[TBL] [Abstract][Full Text] [Related]
44. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD.
Roberts MM; Dyson P; Rawling C; Thorp D; Rawling T; White D; Horvath N; Bardy P; Hui CH; Dart GW; To LB; Hughes TP
Cytotherapy; 2003; 5(6):534-41. PubMed ID: 14660049
[TBL] [Abstract][Full Text] [Related]
45. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.
Fozza C; Szydlo RM; Abdel-Rehim MM; Nadal E; Goldman JM; Apperley JF; Dazzi F
Br J Haematol; 2007 Mar; 136(6):833-6. PubMed ID: 17341269
[TBL] [Abstract][Full Text] [Related]
46. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
47. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
[TBL] [Abstract][Full Text] [Related]
48. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
49. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
50. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Kröger N; Zabelina T; Ayuk F; Atanackovic D; Schieder H; Renges H; Zander A
Exp Hematol; 2006 Jun; 34(6):770-5. PubMed ID: 16728282
[TBL] [Abstract][Full Text] [Related]
51. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome.
Lokhorst HM; Schattenberg A; Cornelissen JJ; van Oers MH; Fibbe W; Russell I; Donk NW; Verdonck LF
J Clin Oncol; 2000 Aug; 18(16):3031-7. PubMed ID: 10944138
[TBL] [Abstract][Full Text] [Related]
52. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
53. Autologous GVHD following PBSCT, with evidence for a graft-versus-myeloma effect.
Byrne JL; Carter GI; Ellis I; Haynes AP; Russell NH
Bone Marrow Transplant; 1997 Sep; 20(6):517-20. PubMed ID: 9313888
[TBL] [Abstract][Full Text] [Related]
54. [Therapy of multiple myeloma by allogeneic bone marrow transplantation].
Heyll A; Aul C; Söhngen D; Meckenstock G; Arning M; Wurm R; Schmitt G; Schneider W
Dtsch Med Wochenschr; 1991 May; 116(22):852-6. PubMed ID: 1903693
[TBL] [Abstract][Full Text] [Related]
55. Successful treatment of refractory donor lymphocyte infusion-induced immune-mediated pancytopenia with rituximab.
Kato I; Umeda K; Awaya T; Yui Y; Niwa A; Fujino H; Matsubara H; Watanabe K; Heike T; Adachi N; Endo F; Mizukami T; Nunoi H; Nakahata T; Adachi S
Pediatr Blood Cancer; 2010 Feb; 54(2):329-31. PubMed ID: 19890900
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic bone marrow transplantation in multiple myeloma: a report of four cases.
Nikoskelainen J; Koskela K; Kätkä K; Pelliniemi TT; Kulmala J; Salmi T; Toivanen A
Bone Marrow Transplant; 1988 Sep; 3(5):495-500. PubMed ID: 2973361
[TBL] [Abstract][Full Text] [Related]
57. Donor lymphocyte infusion at unstable mixed chimerism in an allogeneic BMT recipient for chronic granulomatous disease.
Akioka S; Itoh H; Ueda I; Matsumoto Y; Iwami H; Tsunamoto K; Hibi S; Todo S; Sawada T; Imashuku S
Bone Marrow Transplant; 1998 Sep; 22(6):609-11. PubMed ID: 9758355
[TBL] [Abstract][Full Text] [Related]
58. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA; Fuchs EJ; Noga SJ; O'Donnell PV; Ambinder RF; Diehl L; Borrello I; Vogelsang GB; Miller CB; Flinn IA; Brodsky RA; Marcellus D; Jones RJ
Biol Blood Marrow Transplant; 2003 May; 9(5):312-9. PubMed ID: 12766881
[TBL] [Abstract][Full Text] [Related]
59. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.
Orsini E; Alyea EP; Chillemi A; Schlossman R; McLaughlin S; Canning C; Soiffer RJ; Anderson KC; Ritz J
Biol Blood Marrow Transplant; 2000; 6(4):375-86. PubMed ID: 10917573
[TBL] [Abstract][Full Text] [Related]
60. Successful treatment of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation with donor lymphocyte infusion failed to prevent recurrence of primary disease: a case report.
Cesaro S; Messina C; Rosolen A; Putti MC; Sainati L; Destro R; Gazzola MV; Varotto S; De Silvestro G; Scarzello G; Spinelli M; Pillon M; Zanesco L
Bone Marrow Transplant; 1999 Mar; 23(6):625-8. PubMed ID: 10217195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
